Inpharmus

Executive Summary

Inpharmus (formerly TRPharm) is a private, global pharmaceutical company headquartered in Madrid, Spain, with a strategic focus on providing access to innovative and specialty medicines across key emerging markets. Founded in 2018, the company operates a platform business model, leveraging regional expertise and a physical presence in nearly 20 countries to bridge healthcare needs from diagnosis to treatment. Inpharmus targets high-growth therapeutic areas including immunology, oncology, rheumatology, and rare diseases, with a diversified portfolio encompassing biologics, biosimilars, and small molecules. By partnering with biotech and pharma innovators, the company aims to accelerate patient access and capture value in underserved regions with expanding healthcare infrastructure. While still relatively young, Inpharmus has established a broad operational footprint and is positioned to benefit from the increasing demand for specialty medicines in emerging economies. However, the company's lack of disclosed financials or late-stage pipeline data limits visibility into its near-term revenue trajectory, making conviction dependent on execution of its partnership-driven growth strategy.

Upcoming Catalysts (preview)

• TBDNew in-licensing or partnership deal for a late-stage biosimilar or specialty product70% success
• TBDGeographic expansion into an additional emerging market country (e.g., Southeast Asia or Africa)60% success
• TBDFirst commercial launch or regulatory approval in a new therapeutic area (e.g., rare disease)50% success